U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283731) titled 'Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma' on Dec. 12.
Brief Summary: To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS
Study Start Date: June 02, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 2
Zanzalintinib
Pembrolizumab
Advanced/Metastatic
Soft-Tissue Sarcoma
Intervention:
DRUG: Zanzalintinib
Given by po
DRUG: Pembrolizumab
Given by iv
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services...